Development of Dendritic Cell vaccines as future treatment of patients with cancer

Development of Dendritic Cell vaccines as future treatment of patients with cancer - Anti-cancer DC vaccine development

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55686

Enrollment

Registered

2017-08-17

Start date

2018-07-11

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

het betreft enkel afname van bloedcellen via aferese bij gezonde vrijwilligers voor verbeteren en optimaliseren productie methode cellulaire immunotherapie NA

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers, no underlying disease Age 18 or older Male or Female

Exclusion criteria

Exclusion criteria: no venous access

Design outcomes

Primary

Measure	Time frame
The primary outcome that is relevant: 1. a strong T cell response in vitro with a readout of Interferon gamma production.	—

Countries

Netherlands

Outcome results